Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211808 | 0.91 | MAPKAPK5 (0.81) | MAPKAPK5TTK | |
| SCHEMBL10169134 | 0.89 | MAPKAPK5 (0.67) | MAPKAPK5TTK | |
| SCHEMBL5573262 | 0.89 | MAPKAPK5 (0.84) | MAPKAPK5TTK | |
| SCHEMBL10169146 | 0.84 | MAPKAPK5 (0.68) | MAPKAPK5TTK | |
| SCHEMBL10169151 | 0.84 | MAPKAPK5 (0.68) | MAPKAPK5TTK | |
| SCHEMBL10169116 | 0.83 | MAPKAPK5 (0.68) | MAPKAPK5TTK | |
| SCHEMBL12443278 | 0.83 | MAPKAPK5 (0.48) | MAPKAPK5TTK | |
| SCHEMBL5574894 | 0.81 | MAPKAPK5 (0.73) | MAPKAPK5TTK | |
| SCHEMBL4393746 | 0.81 | MAPKAPK5 (0.72) | MAPKAPK5TTK | |
| SCHEMBL2068099 | 0.80 | MAPKAPK5 (1.00) | MAPKAPK5TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885TTK 4173/4885 |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885TTK 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.